The World Health Organization recently recommended that governments increase access to a new injectable HIV prevention medication called lenacapavir. This medicine requires only two injections per year, making it much easier for people in remote or underserved areas to receive. Currently, access is mostly limited to clinical trial settings, which leaves many people without options. For individuals facing poverty or social stigma, getting a daily pill or even an every-other-month shot can be extremely difficult.
The WHO’s recommendation came at a time when the United States government was already reducing support for global health programs. USAID had been responsible for about three-quarters of donor-funded HIV prevention efforts worldwide. This reduction in support has made it harder for many countries to obtain the tools needed to fight the disease.
People who inject drugs are especially at risk, and they often lack access to clean needles or other harm reduction resources. A major pharmaceutical company has offered lower prices for long-acting HIV drugs in developing nations. However, the same company still charges full price in countries classified as upper middle-income. Countries like Brazil, Mexico, and Colombia are among those excluded from these lower rates.
This approach has drawn criticism for leaving many people behind despite advances in prevention.
The decline in public trust in health officials has also affected how these new tools are received. A recent congressional hearing highlighted tensions around public health leadership during the pandemic. Some members of Congress questioned the actions and transparency of top health officials. This has contributed to a broader loss of confidence in public health institutions.
Historically, public resistance to health measures has existed for many decades. Examples include opposition to mask mandates during past flu outbreaks.
Experts say the pandemic revealed how important it is for health leaders to explain uncertainty clearly. They also pointed out how public health must balance saving lives with respecting personal freedom. This tension has become more visible in recent years with debates over vaccines and public health mandates.
The number of measles cases in the U.S. has risen sharply, reaching levels not seen since the 1990s. These outbreaks have led to serious illness and even death in some cases.
Some public health advocates have expressed concern about the influence of groups opposing certain health policies. These groups have focused on diet, environmental toxins, and other lifestyle issues. While their concerns are valid, they sometimes conflict with traditional public health goals.
Still, there is potential for collaboration between these groups and public health officials. Both sides share an interest in improving health outcomes and reducing risks.
Experts say that better communication and clearer explanations are needed to rebuild trust. They believe that public health leaders must be more open about how decisions are made and what uncertainties exist.
The challenge now is to ensure that new tools like lenacapavir are not held back by political or financial barriers. Without proper access, the benefits of these treatments may never reach those who need them most.
Global health efforts depend on cooperation and funding, both of which are under strain. The situation highlights the need for better support systems and clearer communication across all levels of public health.
Image: DarkoStojanovic / Pixabay